Cerus Corporation (CERS) Set to Announce Quarterly Earnings on Thursday
Cerus Corporation (NASDAQ:CERS) will issue its quarterly earnings data after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.
Cerus Corporation (NASDAQ:CERS) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). Cerus Corporation had a negative return on equity of 120.31% and a negative net margin of 164.39%. The business had revenue of $9.53 million during the quarter, compared to analysts’ expectations of $9.14 million. During the same quarter last year, the business posted ($0.18) EPS. The business’s revenue was up 3.0% on a year-over-year basis. On average, analysts expect Cerus Corporation to post $-0.64 EPS for the current fiscal year and $-0.48 EPS for the next fiscal year.
Shares of Cerus Corporation (NASDAQ:CERS) opened at 2.87 on Thursday. The firm has a 50-day moving average price of $2.81 and a 200 day moving average price of $2.79. The stock’s market cap is $313.22 million. Cerus Corporation has a 12-month low of $1.93 and a 12-month high of $5.91.
Several research analysts have issued reports on the company. BidaskClub upgraded Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. ValuEngine lowered Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research lowered Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. Finally, Cowen and Company set a $6.00 target price on Cerus Corporation and gave the company a “buy” rating in a research report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $7.00.
In other Cerus Corporation news, insider Laurence M. Corash bought 92,796 shares of the company’s stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $2.45 per share, for a total transaction of $227,350.20. Following the completion of the transaction, the insider now directly owns 1,375,711 shares of the company’s stock, valued at $3,370,491.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 7.40% of the stock is owned by insiders.
Cerus Corporation Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.